Guido Mieth By Marshall Gordon, Elisa Mazen and Charine Park Diabetes and Obesity Markets Large and Growing Drugs based on GLP-1 are developing into a mega blockbuster market for the treatment of diabetes and obesity. Danish pharmaceutical maker Novo Nordisk (NVO) has been involved for decades in the treatment of diabetes and is pioneering the advanced pharmaceutical treatment of obesity. ClearBridge initially purchased Novo in 2001, well ahead of the first clinical trials for its type 2 diabetes treatment ...

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: NGM has agreed to be acquired by affiliat ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community. The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives. One area of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) 14 Schoolhouse Road Catalent, Inc. Somerset, New Jersey 08873 (Exact name of registrant as specified in its chart ...

Catalent, Inc. (CTLT) reported second-quarter fiscal 2024 adjusted loss per share of 24 cents against the year-over-year period’s earnings per share (EPS) of 67 cents. The metric was wider than the Zacks Consensus Estimate of a loss of 3 cents per share.The adjustments include charges related to amortization, and acquisition, integration and other special items’ costs, among others.The company’s GAAP loss per share was $1.12 during the quarter, against the year-over-year period’s EPS of 44 cents.Revenues in ...

Catalent (CTLT) reported $1.03 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 10.2%. EPS of -$0.24 for the same period compares to $0.67 a year ago.The reported revenue represents a surprise of +1.79% over the Zacks Consensus Estimate of $1.01 billion. With the consensus EPS estimate being -$0.03, the EPS surprise was -700.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023. “I am proud of the progress the Catalent team made in our second quarter and our ongoing momentum, including strong non-COVID sequential revenue growth in both the Biologics and PCH segments. We also continued to invest in our operational improveme ...

Key PointsFinancials, healthcare, utilities and energy often, but not always, perform well when interest rates remain high.Demand for utilities and healthcare remains strong even in a high-rate environment, although the utilities sector has challenges related to capital investment and cost of borrowing.Energy is facing obstacles relating to geopolitical concerns and excess capacity. 5 stocks we like better than AlphabetLarge bank stocks such as Berkshire Hathaway Inc. NYSE: BRK.B, JPMorgan Chase & Co. NYSE: ...

Catalent’s (CTLT) shares rose 7.2% so far this week. The company’s share price surged following the announcement of its acquisition by Novo Holdings, the parent company of Novo Nordisk (NVO) .Catalent entered into a merger agreement with Novo Nordisk’s parent company on Feb 5. Per the agreement, NVO’s parent company will acquire all outstanding shares of Catalent for $63.50 per share in cash. The deal values Catalent at $16.5 billion on an enterprise value basis.The offered price for each share of CTLT repr ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...